Figure 1: SCREEN-WELL® Nephrotoxicity Library Enzo Life Sciences, Inc. introduces the SCREEN-WELL® Nephrotoxicity Library, a focused collection of 83 compounds with defined and diverse nephrotoxicity, including analgesic nephropathy, interstitial nephritis, glomerularopathy, proximal and distal tubulopathy, acute renal failure, chronic kidney disease, and more. A variety of structurally and mechanistically different compound classes are included, as well as nontoxic controls. This library is an essential cost-effective tool for predictive toxicology screening and assay development.
The comprehensive SCREEN-WELL® Compound Library product line incorporates years of scientific expertise resulting in libraries that contain the right compounds in the right combination, and now features a growing collection of targeted toxicity libraries including Cardiotoxicity, Hepatotoxicity, Hematopoietic Toxicity, Nephrotoxicity, and Myotoxicity. Custom libraries are available upon request.
With the launch of the SCREEN-WELL® Nephrotoxicity Library, Enzo Life Sciences expands their existing portfolio of innovative research tools for early safety assessment. Enzo’s CELLESTIAL® fluorescence-based live cell assays are designed to help assess the impact of toxic agents on overall cell function while our toxicity libraries are useful for high-throughput screening of organ-associated toxicity profiles. Combining these technologies allows Enzo to offer an elegant system for the discovery, analysis and quantification of biomarkers relevant to predictive toxicology.
Enzo Life Sciences, Inc. is a wholly owned subsidiary of Enzo Biochem, Inc. headquartered in Farmingdale, New York. The company is focused on providing innovative life science research reagents worldwide based on over 30 years of successful experience in building strong international market recognition, implementing outstanding operational capabilities, and establishing a state-of-the-art electronic information and ordering marketplace.
Enzo Life Sciences, Inc. is a recognized leader in labeling and detection technologies across research and diagnostic markets. Our strong portfolio of assay kits, libraries, proteins, antibodies, peptides, and small molecules provides life science researchers tools for target identification/validation, drug discovery, cellular analysis, high content analysis, gene expression analysis, nucleic acid detection, and protein biochemistry and detection.
New Product Release
Date: June 11th 2015
For additional Information, please contact:
Kara Cannon, Global Head of Marketing
1-631-694-7070 x 145
